デフォルト表紙
市場調査レポート
商品コード
1009534

癌医療におけるフローサイトメトリーの世界市場 (2021-2031年):市場予測 (製品タイプ・技術・癌の種類・用途・エンドユーザー別)・国別分析 (16カ国)・競合分析

Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 257 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.65円
癌医療におけるフローサイトメトリーの世界市場 (2021-2031年):市場予測 (製品タイプ・技術・癌の種類・用途・エンドユーザー別)・国別分析 (16カ国)・競合分析
出版日: 2021年06月03日
発行: BIS Research Inc.
ページ情報: 英文 257 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

癌医療におけるフローサイトメトリーの市場規模は予測期間中12.02%のCAGRで推移し、2031年には52億5000万米ドルの規模に成長すると予測されています。

血液悪性腫瘍の発症率の上昇、個別化治療や精密医療に対する消費者の意識の高まりなどの要因が同市場の成長を推進しています。

当レポートでは、世界の癌医療におけるフローサイトメトリーの市場を調査し、市場の定義と概要、法規制上の枠組み、市場成長への各種影響因子の分析、市場規模の推移・予測、製品タイプ・技術・癌の種類・用途・エンドユーザー・地域など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 市場の範囲

第3章 調査手法

第4章 市場概要

第5章 産業考察

  • 概要
  • 法的要件・枠組み:米国
  • 法的要件・枠組み:欧州
  • 法的要件・枠組み:アジア太平洋

第6章 市場力学

  • 概要
  • 影響分析
  • 市場推進因子
  • 市場抑制因子
  • 市場機会

第7章 競合情勢

  • 製品発売
  • 提携・協力
  • 買収
  • 製品の承認・事業の拡大
  • 成長シェア分析
  • MRDテスト技術の競合分析

第8章 市場分析・予測:製品タイプ別

  • 概要
  • アッセイ・キット
  • 機器
  • 試薬・消耗品
  • ソフトウェア

第9章 市場分析・予測:技術別

  • 概要
  • セルベース
  • ビーズベース

第10章 市場分析・予測:癌の種類別

  • 概要
  • 血液悪性腫瘍
    • リンパ腫
    • 白血病
    • 骨髄腫
    • その他
  • 固形腫瘍
    • 乳癌
    • 前立腺癌
    • 結腸直腸癌
    • 肺癌
    • その他

第11章 市場分析・予測:用途別

  • 概要
  • トランスレーショナルリサーチ
  • 臨床応用
    • スクリーニング・診断
    • 治療モニタリング

第12章 市場分析・予測:エンドユーザー別

  • 概要
  • 診断ラボ
  • 病院・クリニック
  • 学術・研究機関
  • その他

第13章 市場分析・予測:地域・主要国別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域

第14章 企業プロファイル

  • Agilent Technologies, Inc.
  • Apogee Flow Systems Ltd.
  • Becton, Dickinson and Company
  • bioAffinity Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cytek Biosciences
  • Cytognos, S.L.
  • Danaher Corporation
  • Miltenyi Biotec B.V. & Co. KG
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • NeoGenomics Laboratories, Inc.
  • Sony Corporation
  • Thermo Fisher Scientific Inc.
図表

List of Tables

  • Table 6.1: Likert Scale
  • Table 6.2: Impact Analysis of Market Drivers
  • Table 6.3: Impact Analysis of Market Restraints

List of Figures

  • Figure 1: Prevalence of Hematological Malignancies in the U.S., 2013-2016
  • Figure 2: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018
  • Figure 3: Impact Analysis of Market Drivers and Market Challenges on Global Flow Cytometry in Oncology Market
  • Figure 4: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
  • Figure 5: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
  • Figure 6: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
  • Figure 7: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020 and 2031
  • Figure 8: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020 and 2031
  • Figure 9: Global Flow Cytometry in Oncology: Market Snapshot
  • Figure 2.1: Market Segmentation of Global Flow Cytometry in Oncology Market
  • Figure 3.1: Global Flow Cytometry in Oncology Market: Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 4.2: Global Flow Cytometry in Oncology Market: COVID-19 Impact
  • Figure 6.1: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2016
  • Figure 6.2: Estimated New Cases of Hematological Cancer, 2020
  • Figure 7.1: Share of Key Developments and Strategies, January 2017-May 2021
  • Figure 7.2: Number of Product Launches (by Company), January 2017-May 2021
  • Figure 7.3: Share of Synergistic Activities (by Company), January 2017-May 2021
  • Figure 7.4: Share of Acquisitions (by Company), January 2017-May 2021
  • Figure 7.5: Market Share Analysis for Global Flow Cytometry in Oncology Market, $Million, 2019 and 2020
  • Figure 7.6: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Company), 2020
  • Figure 7.7: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Technology), 2020-2031
  • Figure 7.8: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Type of Cancer), 2020-2031
  • Figure 7.9: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Application), 2020-2031
  • Figure 7.10: Comparative Assessment of Technologies Used in MRD Testing
  • Figure 8.1: Global Flow Cytometry in Oncology Market (by Product Type)
  • Figure 8.2: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
  • Figure 8.3: Global Flow Cytometry in Oncology Market (Assays and Kits), $Million, 2020-2031
  • Figure 8.4: Global Flow Cytometry in Oncology Market (Instruments), $Million, 2020-2031
  • Figure 8.5: Global Flow Cytometry in Oncology Market (Reagents and Consumables), $Million, 2020-2031
  • Figure 8.6: Global Flow Cytometry in Oncology Market (Software), $Million, 2020-2031
  • Figure 9.1: Global Flow Cytometry in Oncology Market (by Technology)
  • Figure 9.2: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
  • Figure 9.3: Global Flow Cytometry in Oncology Market (Cell-Based), $Million, 2020-2031
  • Figure 9.4: Global Flow Cytometry in Oncology Market (Bead-Based), $Million, 2020-2031
  • Figure 10.1: Global Flow Cytometry in Oncology Market (by Type of Cancer)
  • Figure 10.2: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
  • Figure 10.3: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020-2031
  • Figure 10.4: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020 and 2031
  • Figure 10.5: Global Flow Cytometry in Oncology Market (Lymphoma), $Million, 2020-2031
  • Figure 10.6: Global Flow Cytometry in Oncology Market (Leukemia), $Million, 2020-2031
  • Figure 10.7: Global Flow Cytometry in Oncology Market (Myeloma), $Million, 2020-2031
  • Figure 10.8: Global Flow Cytometry in Oncology Market (Other Hematological Malignancies), $Million, 2020-2031
  • Figure 10.9: Global Flow Cytometry in Oncology Market for Hematological Malignancies (by Technology), $Million, 2020-2031
  • Figure 10.10: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020-2031
  • Figure 10.11: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020 and 2031
  • Figure 10.12: Global Flow Cytometry in Oncology Market (Breast Cancer), $Million, 2020-2031
  • Figure 10.13: Global Flow Cytometry in Oncology Market (Prostate Cancer), $Million, 2020-2031
  • Figure 10.14: Global Flow Cytometry in Oncology Market (Colorectal Cancer), $Million, 2020-2031
  • Figure 10.15: Global Flow Cytometry in Oncology Market (Lung Cancer), $Million, 2020-2031
  • Figure 10.16: Global Flow Cytometry in Oncology Market (Other Solid Tumors), $Million, 2020-2031
  • Figure 10.17: Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology), $Million, 2020-2031
  • Figure 11.1: Global Flow Cytometry in Oncology Market (by Application)
  • Figure 11.2: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031
  • Figure 11.3: Global Flow Cytometry in Oncology Market (Translational Research), $Million, 2020-2031
  • Figure 11.4: Global Flow Cytometry in Oncology Market (by Clinical Applications), $Million, 2020 and 2031
  • Figure 11.5: Global Flow Cytometry in Oncology Market (Screening and Diagnostics), $Million, 2020-2031
  • Figure 11.6: Global Flow Cytometry in Oncology Market (Treatment Monitoring), $Million, 2020-2031
  • Figure 12.1: Global Flow Cytometry in Oncology Market (by End User)
  • Figure 12.2: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031
  • Figure 12.3: Global Flow Cytometry in Oncology Market (Diagnostic Laboratories), $Million, 2020-2031
  • Figure 12.4: Global Flow Cytometry in Oncology Market (Hospitals and Healthcare Clinics), $Million, 2020-2031
  • Figure 12.5: Global Flow Cytometry in Oncology Market (Academic and Research Institutions), $Million, 2020-2031
  • Figure 12.6: Global Flow Cytometry in Oncology Market (Other End Users), $Million, 2020-2031
  • Figure 13.1: Global Flow Cytometry in Oncology Market (by Region)
  • Figure 13.2: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
  • Figure 13.3: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
  • Figure 13.4: North America Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.5: North America: Market Dynamics
  • Figure 13.6: North America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.7: U.S. Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.8: Canada Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.9: North America Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.10: Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.11: Europe: Market Dynamics
  • Figure 13.12: Europe Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.13: Germany Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.14: U.K. Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.15: France Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.16: Italy Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.17: Spain Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.18: Netherlands Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.19: Rest-of-Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.20: Europe Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.21: Asia-Pacific Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.22: Asia-Pacific: Market Dynamics
  • Figure 13.23: APAC Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.24: China Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.25: Japan Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.26: India Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.27: Australia Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.28: South Korea Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.29: Singapore Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.30: RoAPAC Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.31: APAC Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.32: Latin America Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.33: Latin America: Market Dynamics
  • Figure 13.34: Latin America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
  • Figure 13.35: Brazil Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.36: Mexico Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.37: RoLA Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.38: LATAM Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 13.39: Rest-of-the-World Flow Cytometry in Oncology Market, $Million, 2020-2031
  • Figure 13.40: Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
  • Figure 14.1: Total Number of Companies Profiles
  • Figure 14.2: Agilent Technologies, Inc.: Product Portfolio
  • Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
  • Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 14.8: Apogee Flow Systems Ltd.: Product Portfolio
  • Figure 14.9: Apogee Flow Systems Ltd.: SWOT Analysis
  • Figure 14.10: Becton, Dickinson and Company: Product Portfolio
  • Figure 14.11: Becton, Dickinson and Company: Overall Financials, 2018-2020
  • Figure 14.12: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
  • Figure 14.13: Becton, Dickinson and Company: Revenue (by Region), 2018-2020
  • Figure 14.14: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
  • Figure 14.15: Becton, Dickinson and Company: SWOT Analysis
  • Figure 14.16: bioAffinity Technologies, Inc.: Product Portfolio
  • Figure 14.17: bioAffinity Technologies, Inc.: SWOT Analysis
  • Figure 14.18: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 14.19: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 14.20: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.22: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.23: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 14.24: Bio-Techne Corporation: Product Portfolio
  • Figure 14.25: Bio-Techne Corporation: Overall Financials, 2018-2020
  • Figure 14.26: Bio-Techne Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.27: Bio-Techne Corporation: Revenue (by Region), 2018-2020
  • Figure 14.28: Bio-Techne Corporation: R&D Expenditure, 2018-2020
  • Figure 14.29: Bio-Techne Corporation: SWOT Analysis
  • Figure 14.30: Cytek Biosciences: Product Portfolio
  • Figure 14.31: Cytek Biosciences: SWOT Analysis
  • Figure 14.32: Cytognos, S.L.: Product Portfolio
  • Figure 14.33: Cytognos, S.L.: SWOT Analysis
  • Figure 14.34: Danaher Corporation: Product Portfolio
  • Figure 14.35: Danaher Corporation: Overall Financials, 2018-2020
  • Figure 14.36: Danaher Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.37: Danaher Corporation: Revenue (by Region), 2018-2020
  • Figure 14.38: Danaher Corporation: R&D Expenditure, 2018-2020
  • Figure 14.39: Danaher Corporation: SWOT Analysis
  • Figure 14.40: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
  • Figure 14.41: Miltenyi Biotec B.V. & Co. KG: SWOT Analysis
  • Figure 14.42: Laboratory Corporation of America Holdings: Service Portfolio
  • Figure 14.43: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
  • Figure 14.44: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
  • Figure 14.45: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 14.46: Luminex Corporation: Product Portfolio
  • Figure 14.47: Luminex Corporation: Overall Financials, 2018-2020
  • Figure 14.48: Luminex Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.49: Luminex Corporation: Revenue (by Region), 2018-2020
  • Figure 14.50: Luminex Corporation: R&D Expenditure, 2018-2020
  • Figure 14.51: Luminex Corporation: SWOT Analysis
  • Figure 14.52: NeoGenomics Laboratories, Inc.: Service Portfolio
  • Figure 14.53: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
  • Figure 14.54: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.55: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.56: NeoGenomics Laboratories, Inc.: SWOT Analysis
  • Figure 14.57: Sony Corporation: Product Portfolio
  • Figure 14.58: Sony Corporation: Overall Financials, 2018-2020
  • Figure 14.59: Sony Corporation: Revenue (by Segment): 2018-2020
  • Figure 14.60: Sony Corporation: Revenue (by Region), 2018-2020 (E)
  • Figure 14.61: Sony Corporation: R&D Expenditure, 2018-2020 (E)
  • Figure 14.62: Sony Corporation: SWOT Analysis
  • Figure 14.63: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 14.64: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
  • Figure 14.65: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
  • Figure 14.66: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
  • Figure 14.67: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 14.68: Thermo Fisher Scientific Inc.: SWOT Analysis
目次
Product Code: BHP1070SA

Global Flow Cytometry in Oncology Market to Reach $5.25 Billion by 2031

Market Report Coverage - Flow Cytometry in Oncology

Market Segmentation

  • Product Type - Assays and Kits, Instruments, Reagents and Consumables, and Software
  • Technology - Cell-Based and Bead-Based
  • Type of Cancer - Hematological Malignancies (Lymphoma, Leukemia, Myeloma, and Other Hematological Malignancies) and Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, and Other Solid Tumors)
  • Application - Translational Research and Clinical Applications (Screening and Diagnostics, and Treatment Monitoring)
  • End User - Diagnostic Laboratories, Hospitals and Healthcare Centers, Academic and Research Institutions, and Other End Users

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Market Growth Drivers

  • Rising Incidence of Hematological Malignancies
  • Increasing Fund Infusions for Hematological Malignancies
  • Growing Consumer Awareness for Tailored Therapy and Precision Medicine

Market Challenges

  • False Negatives and Positives
  • Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment

Market Opportunities

  • Technological Evolution in the Field of Flow Cytometry
  • Growth in Solid Tumor Applications of Flow Cytometry

Key Surgical Instrument Tracking Devices Companies Profiled

Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytek Biosciences, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • How is flow cytometry revolutionizing the field of oncology?
  • What are the major market drivers, challenges, and opportunities in the global flow cytometry in oncology market?
  • What are the underlying structures resulting in the emerging trends within the global flow cytometry in oncology market?
  • How is the COVID-19 pandemic impacting the global flow cytometry in oncology ecosystem?
  • What are the key development strategies that are being implemented by the major players in order to sustain the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of flow cytometry in the field of oncology?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
    • Product Type (assays and kits, instruments, reagents and consumables, and software)
    • Technology (cell-based and bead-based)
    • Type of Cancer (hematological malignancies and solid tumor)
    • Application (translational research and clinical applications)
    • End User (diagnostic laboratories, hospitals and healthcare clinics, academic and research institutions, and other end users)
    • Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
  • What are the growth opportunities for the companies in the region of their operation?
  • Who are the leading players with significant offerings in the global flow cytometry in oncology market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found flow cytometry in oncology industry to be one of the most rapidly evolving and dynamic markets. The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031. The market is driven by certain factors, including rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine.

The market is favored by the developments in the field of cancer diagnostic testing and its attributes such as flow cytometry. Currently, the flow cytometry in oncology industry is witnessing an upsurge due to the rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine. Additionally, high adoption of flow cytometry instruments by the end users to conduct cancer diagnosis and therapeutic monitoring are some of the critical factors that are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust flow cytometry solutions for a wide range of applications, including translational research and clinical applications, to support researchers and physicians in unraveling insights pertaining to cellular alterations.

Within the research report, the market is segmented on the basis of product type, technology, type of cancer, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of cases associated with cancer, particularly hematological malignancies, has created a buzz among the biotechnology companies to further invest in the development of cancer diagnostic solutions such as flow cytometry, further aiding physicians to offer value-based therapeutic outcomes to patients. Becton, Dickinson and Company has been a pioneer in this field and has been a significant competitor in this market due to the presence of a diverse product portfolio and intense market penetration.

On the basis of region, in 2020, North America held the largest share of the flow cytometry in oncology market due to high infusion of funding from the government organizations for conducting cancer research, growing incidence and prevalence of cancer, growing awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Flow Cytometry in Oncology Market: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Application of Flow Cytometry in Oncology (Hematological vs. Solid Tumors)
  • 4.3 Market Footprint and Growth Potential
  • 4.4 COVID-19 Impact: Global Flow Cytometry in Oncology Market

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Framework in U.S.
  • 5.3 Legal Requirements and Framework in Europe
  • 5.4 Legal Requirements and Framework in Asia-Pacific
    • 5.4.1 China
    • 5.4.2 Japan

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Rising Incidence of Hematological Malignancies
    • 6.3.2 Increasing Fund Infusions for Hematological Malignancies
    • 6.3.3 Growing Consumer Awareness for Tailored Therapy and Precision Medicine
  • 6.4 Market Restraints
    • 6.4.1 False Negatives and Positives
    • 6.4.2 Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment
  • 6.5 Market Opportunities
    • 6.5.1 Technological Evolution in the Field of Flow Cytometry
      • 6.5.1.1 Emergence of Multiparametric Flow Cytometry for Hematologic Malignancies
      • 6.5.1.2 Growing Focus on Next-Generation Flow Cytometry
    • 6.5.2 Growth in Solid Tumor Applications of Flow Cytometry

7 Competitive Landscape

  • 7.1 Product Launches
  • 7.2 Synergistic Activities
  • 7.3 Acquisitions
  • 7.4 Product Approvals and Business Expansion Activities
  • 7.5 Market Share Analysis, 2019-2020
  • 7.6 Growth Share Analysis
    • 7.6.1 Growth Share Analysis (by Company)
    • 7.6.2 Growth Share Analysis (by Technology)
    • 7.6.3 Growth Share Analysis (by Type of Cancer)
    • 7.6.4 Growth Share Analysis (by Application)
  • 7.7 Competitive Assessment of Different Technologies Utilized for MRD Testing

8 Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020-2031

  • 8.1 Overview
  • 8.2 Assays and Kits
  • 8.3 Instruments
  • 8.4 Reagents and Consumables
  • 8.5 Software

9 Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020-2031

  • 9.1 Overview
  • 9.2 Cell-Based
  • 9.3 Bead-Based

10 Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031

  • 10.1 Overview
  • 10.2 Hematological Malignancies
    • 10.2.1 Lymphoma
    • 10.2.2 Leukemia
    • 10.2.3 Myeloma
    • 10.2.4 Other Hematological Malignancies
    • 10.2.5 Global Flow Cytometry Market for Hematological Malignancies (by Technology)
  • 10.3 Solid Tumors
    • 10.3.1 Breast Cancer
    • 10.3.2 Prostate Cancer
    • 10.3.3 Colorectal Cancer (CRC)
    • 10.3.4 Lung Cancer
    • 10.3.5 Other Solid Tumors
    • 10.3.6 Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology)

11 Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031

  • 11.1 Overview
  • 11.2 Translational Research
  • 11.3 Clinical Applications
    • 11.3.1 Screening and Diagnostics
    • 11.3.2 Treatment Monitoring

12 Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031

  • 12.1 Overview
  • 12.2 Diagnostic Laboratories
  • 12.3 Hospitals and Healthcare Clinics
  • 12.4 Academic and Research Institutions
  • 12.5 Other End Users

13 Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
    • 13.2.3 North America Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 U.K.
    • 13.3.3 France
    • 13.3.4 Italy
    • 13.3.5 Spain
    • 13.3.6 Netherlands
    • 13.3.7 Rest-of-Europe
    • 13.3.8 Europe Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.4 Asia-Pacific (APAC)
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 South Korea
    • 13.4.6 Singapore
    • 13.4.7 Rest-of-Asia-Pacific (RoAPAC)
    • 13.4.8 Asia-Pacific Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.5 Latin America (LATAM0
    • 13.5.1 Brazil
    • 13.5.2 Mexico
    • 13.5.3 Rest-of-Latin America (RoLA)
    • 13.5.4 Latin America Flow Cytometry in Oncology Market (by Type of Cancer)
  • 13.6 Rest-of-the-World (RoW)
    • 13.6.1 Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer)

14 Company Profiles

  • 14.1 Overview
  • 14.2 Agilent Technologies, Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Agilent Technologies, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights About Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 Apogee Flow Systems Ltd.
    • 14.3.1 Company Overview
    • 14.3.2 Role of Apogee Flow Systems Ltd. in the Global Flow Cytometry in Oncology Market
    • 14.3.3 SWOT Analysis
  • 14.4 Becton, Dickinson and Company
    • 14.4.1 Company Overview
    • 14.4.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 bioAffinity Technologies, Inc.
    • 14.5.1 Company Overview
    • 14.5.2 Role of bioAffinity Technologies, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.5.3 SWOT Analysis
  • 14.6 Bio-Rad Laboratories, Inc.
    • 14.6.1 Company Overview
    • 14.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 Bio-Techne Corporation
    • 14.7.1 Company Overview
    • 14.7.2 Role of Bio-Techne Corporation in the Global Flow Cytometry in Oncology Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 Cytek Biosciences
    • 14.8.1 Company Overview
    • 14.8.2 Role of Cytek Biosciences in the Global Flow Cytometry in Oncology Market
    • 14.8.3 SWOT Analysis
  • 14.9 Cytognos, S.L.
    • 14.9.1 Company Overview
    • 14.9.2 Role of Cytognos, S.L. in the Global Flow Cytometry in Oncology Market
    • 14.9.3 SWOT Analysis
  • 14.1 Danaher Corporation
    • 14.10.1 Company Overview
    • 14.10.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology Market
    • 14.10.3 Financials
    • 14.10.4 Key Insights About Financial Health of the Company
    • 14.10.5 SWOT Analysis
  • 14.11 Miltenyi Biotec B.V. & Co. KG
    • 14.11.1 Company Overview
    • 14.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Flow Cytometry in Oncology Market
    • 14.11.3 SWOT Analysis
  • 14.12 Laboratory Corporation of America Holdings
    • 14.12.1 Company Overview
    • 14.12.2 Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology Market
    • 14.12.3 Financials
    • 14.12.4 SWOT Analysis
  • 14.13 Luminex Corporation
    • 14.13.1 Company Overview
    • 14.13.2 Role of Luminex Corporation in the Global Flow Cytometry in Oncology Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights About Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 NeoGenomics Laboratories, Inc.
    • 14.14.1 Company Overview
    • 14.14.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
    • 14.14.3 Financials
    • 14.14.4 Key Insights about Financial Health of the Company
    • 14.14.5 SWOT Analysis
  • 14.15 Sony Corporation
    • 14.15.1 Company Overview
    • 14.15.2 Role of Sony Corporation in the Global Flow Cytometry in Oncology Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights About Financial Health of the Company
    • 14.15.5 SWOT Analysis
  • 14.16 Thermo Fisher Scientific Inc.
    • 14.16.1 Company Overview
    • 14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology Market
    • 14.16.3 Financials
    • 14.16.4 Key Insights About Financial Health of the Company
    • 14.16.5 SWOT Analysis